



*Innovating HIV Care*  
Working Towards a Brighter Future



Sunday 13<sup>th</sup> July 15.45–17.45  
*Amphithéâtre Bleu, Level 2,*  
*Le Palais des Congrès*  
2<sup>nd</sup> IAS Conference on HIV  
Pathogenesis and Treatment, Paris



# MASTERS of ART

Satellite Symposium

Photos by PhotoDisc & Superstock used for illustration purposes only

3064/05.03/6

Plan  
**VIRACEPT**<sup>®</sup>  
nelfinavir mesylate

Boosted  
**INVIRASE**<sup>®</sup>  
saquinavir

**FUZEON**<sup>®</sup>  
enfuvirtide



F. Hoffmann-La Roche Ltd  
4070 Basel, Switzerland  
© 2003 All rights reserved  
www.roche-hiv.com

## WELCOME

Dear colleague

This year marks the 20<sup>th</sup> anniversary of the discovery of HIV-1 – twenty years in which new challenges have emerged as quickly as our knowledge of the virus and its pathogenesis has grown. It is now clear that if we are to make the goal of life-long suppression of HIV achievable for all HIV-infected individuals, we must learn how to adapt treatment strategies to make the most of the medicines available to us.

The treatment of HIV/AIDS could be described as having characteristics of both a science and an art. Choosing an active combination of antiretrovirals that will effectively tackle the virus – and maintain quality of life – is an art that requires the application of scientific principles and clinical knowledge to a set of unique, patient-specific circumstances.

It is therefore with great pleasure that we invite you to attend the satellite symposium “Masters of ART”, in which we will discuss emerging strategies for tackling some of the common clinical dilemmas faced by HIV-treating physicians today. We hope you will join us as we discuss different ways in which we can master the art of HIV therapy.

Françoise Brun-Vézinet

Anton Pozniak

**Co-chairs**



## SCIENTIFIC Programme

### Welcome and Introduction

Françoise Brun-Vézinet, France

### Neo-classical ART:

The role of nelfinavir in HIV-HCV co-infected patients  
Douglas Dieterich, USA

### Renaissance ART:

Novel treatment strategies using boosted saquinavir  
Calvin Cohen, USA

### Contemporary ART:

Advancing protease inhibitor treatment to meet changing patient needs  
Anton Pozniak, UK

### ART nouveau:

New analyses to further define the clinical profile of enfuvirtide  
Joep Lange, The Netherlands

### Fine ART:

Achieving optimal patient outcome with enfuvirtide  
James Witek, USA

### Closing comments

Discussion and chairs' concluding remarks



Slides from this symposium will be available from the Roche exhibition stand